The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA ...

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

From my colleague Andrew Joseph: After a bumpy road, Eisai and Biogen’s Alzheimer’s therapy Leqembi has won approval in ...